Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dolutegravir and Darunavir/Cobicistat in Healthy Volunteers
NCT03094507Phase 1Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by St Stephen's AIDS Trust. Primary endpoints: Trough Concentration at 8 weeks, Peak Plasma Concentration at 8 weeks and 3 more. Started Apr 2017; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03094507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094507.